Breaking News Headlines Today | Ground News

See every side of every news story

Stemwell Science News image

News from Stemwell Science News

The Ground News media bias check for Stemwell Science News is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and AllSides.

Is Stemwell Science News credible or reliable? Our Factuality score answers both of those questions. When it comes to Stemwell Science News, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about Stemwell Science News

Where is Stemwell Science News located?Stemwell Science News's Website Stemwell Science News's Twitter

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Stemwell Science News News

CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

100% Center coverage: 1 sources

(MedPage Today) -- Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high rate of non-relapse mortality in patients with multiple myeloma, according to a retrospective study...See the Story

Reactive Oligodendrocytes Promote Glioblastoma Progression through CCL5/CCR5-Mediated Glioma Stem Cell Maintenance

Maryland · Maryland

Reactive Oligodendrocytes Promote Glioblastoma Progression through CCL5/CCR5-Mediated Glioma Stem Cell Maintenance

Researchers utilized single-cell and spatial transcriptomics from primary and recurrent glioblastoma (GBM) tumors, immunohistochemistry, cytokine profiling, and migration assays to show that GBM cells recruit oligodendrocytes to the tumor border via fractalkine signaling. [Neuron] AbstractGraphical Abstract See the Story

Nous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers: A Phase 1b/2 Trial

Nous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers: A Phase 1b/2 Trial

Scientists presented the results from cohort 1 of a Phase Ib/II single-arm trial of Nous-209 for cancer interception in Lynch syndrome carriers. [Nature Medicine] Full Article See the Story

Breaking News Topics Related to Stemwell Science News